Table 3 Correlation of serum LAPTM4B with clinical indicators in patients with LAC (median(IQR))
Characteristics | Number | LAPTM4B(ng/mL) | P value |
|---|---|---|---|
Gender | |||
 Male | 95(43.98%) | 9.478(10.410) | 0.123 |
 Female | 121(56.02%) | 7.664(10.349) | |
Age | |||
  ≤ 60 | 100(46.30%) | 7.695(9.131) | 0.201 |
  > 60 | 116(53.70%) | 9.122(11.981) | |
Smoking | |||
 No | 141(65.28%) | 7.394(10.201) | 0.019 |
 Yes | 75(34.72%) | 10.469(11.220) | |
Hypertension | |||
 No | 157(72.69%) | 8.541(11.009) | 0.819 |
 Yes | 59(27.31%) | 8.249(8.749) | |
Clinical stages | |||
 I + II | 120(55.56%) | 7.315(10.454) | 0.023 |
 III + IV | 96(44.44%) | 9.895(10.420) | |
Depth of infiltration | |||
 T1 + T2 | 170(78.70%) | 7.944(9.834) | 0.079 |
 T3 + T4 | 46(21.30%) | 10.374(10.006) | |
Lymph node metastasis | |||
 No | 119(55.09%) | 7.293(10.323) | 0.011 |
 Yes | 97(44.91%) | 10.225(10.496) | |
Distant metastasis | |||
 No | 158(73.15%) | 8.160(10.278) | 0.381 |
 Yes | 58(26.85%) | 9.283(9.624) | |
ALK-ventana | |||
 Negative | 179(82.87%) | 7.277(8.885) | < 0.001 |
 Positive | 37(17.13%) | 14.190(6.668) | |
EGFR mutations | Â | ||
 Negative | 139(64.35%) | 6.942(7.532) | 0.001 |
 Positive | 77 (35.65%) | 11.205 (14.330) | |